Renal Effects of SGLT2 Inhibitors: An Update

Josselin Nespoux; Volker Vallon

Disclosures

Curr Opin Nephrol Hypertens. 2020;29(2):190-198. 

In This Article

Conclusion

SGLT2 inhibitors target renal glucose reabsorption in the proximal tubule and induce pleiotropic beneficial effects on the renal and cardiovascular systems. The CREDENCE trial indicated that SGLT2 inhibitors also improve renal and cardiovascular outcomes in T2DM patients with CKD despite a lesser blood glucose effect. Clinical and experimental studies and mathematical modeling provided further mechanistic insights on blood glucose-dependent and independent mechanisms underlying the renoprotective effects of SGLT2 inhibition.

Comments

3090D553-9492-4563-8681-AD288FA52ACE

processing....